vs
Lyell Immunopharma, Inc.（LYEL）与RAPT Therapeutics, Inc.（RAPT）财务数据对比。点击上方公司名可切换其他公司
RAPT Therapeutics, Inc.自由现金流更多（$-21.9M vs $-150.8M）
Lyell Immunopharma是一家处于临床阶段的生物技术企业，专注于研发新一代嵌合抗原受体T细胞疗法，用于治疗多种实体瘤，面向北美肿瘤患者群体，致力于满足难治癌症领域未被满足的医疗需求。
Horizon Therapeutics plc是一家生物制药企业，专注于罕见病和风湿性疾病相关药物的研发、生产及商业化，致力于满足相关患者的迫切治疗需求。其产品主要在美国市场销售，2019年美国市场营收占全球总营收的97%，2023年10月被安进公司收购。
LYEL vs RAPT — 直观对比
营收规模更大
LYEL
是对方的Infinity倍
$0
自由现金流更多
RAPT
多$128.9M
$-150.8M
损益表 — Q4 FY2025 vs Q3 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $6.0K | $0 |
| 净利润 | — | $-31.4M |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | -45.5% | — |
| 净利润同比 | 26.7% | -47.7% |
| 每股收益（稀释后） | — | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LYELRAPT
| Q4 25 | $6.0K | — | ||
| Q3 25 | $15.0K | — | ||
| Q2 25 | $8.0K | — | ||
| Q1 25 | $7.0K | — | ||
| Q4 24 | $11.0K | — | ||
| Q3 24 | $34.0K | — | ||
| Q2 24 | $13.0K | — | ||
| Q1 24 | $3.0K | — |
净利润LYELRAPT
| Q4 25 | — | — | ||
| Q3 25 | $-38.8M | — | ||
| Q2 25 | $-42.7M | — | ||
| Q1 25 | $-52.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-44.6M | — | ||
| Q2 24 | $-45.8M | — | ||
| Q1 24 | $-60.7M | — |
营业利润率LYELRAPT
| Q4 25 | — | — | ||
| Q3 25 | -248353.3% | — | ||
| Q2 25 | -589250.0% | — | ||
| Q1 25 | -819528.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -148544.1% | — | ||
| Q2 24 | -396369.2% | — | ||
| Q1 24 | -1852500.0% | — |
净利率LYELRAPT
| Q4 25 | — | — | ||
| Q3 25 | -258973.3% | — | ||
| Q2 25 | -533550.0% | — | ||
| Q1 25 | -745642.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -131126.5% | — | ||
| Q2 24 | -352376.9% | — | ||
| Q1 24 | -2022233.3% | — |
每股收益（稀释后）LYELRAPT
| Q4 25 | — | — | ||
| Q3 25 | $-2.13 | — | ||
| Q2 25 | $-2.89 | — | ||
| Q1 25 | $-0.18 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-3.48 | — | ||
| Q2 24 | $-3.59 | — | ||
| Q1 24 | $-0.24 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.2M | $184.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $248.2M | $172.8M |
| 总资产 | $340.1M | $199.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LYELRAPT
| Q4 25 | $247.2M | — | ||
| Q3 25 | $319.6M | — | ||
| Q2 25 | $276.8M | — | ||
| Q1 25 | $301.2M | — | ||
| Q4 24 | $370.5M | — | ||
| Q3 24 | $440.5M | — | ||
| Q2 24 | $491.1M | — | ||
| Q1 24 | $526.3M | — |
股东权益LYELRAPT
| Q4 25 | $248.2M | — | ||
| Q3 25 | $329.1M | — | ||
| Q2 25 | $298.9M | — | ||
| Q1 25 | $336.5M | — | ||
| Q4 24 | $382.8M | — | ||
| Q3 24 | $530.7M | — | ||
| Q2 24 | $566.5M | — | ||
| Q1 24 | $603.2M | — |
总资产LYELRAPT
| Q4 25 | $340.1M | — | ||
| Q3 25 | $408.0M | — | ||
| Q2 25 | $385.5M | — | ||
| Q1 25 | $429.8M | — | ||
| Q4 24 | $490.9M | — | ||
| Q3 24 | $619.2M | — | ||
| Q2 24 | $654.1M | — | ||
| Q1 24 | $694.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-150.0M | $-21.9M |
| 自由现金流经营现金流 - 资本支出 | $-150.8M | $-21.9M |
| 自由现金流率自由现金流/营收 | -2513400.0% | — |
| 资本支出强度资本支出/营收 | 13000.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-269.1M | $-91.1M |
8季度趋势，按日历期对齐
经营现金流LYELRAPT
| Q4 25 | $-150.0M | — | ||
| Q3 25 | $-28.6M | — | ||
| Q2 25 | $-34.5M | — | ||
| Q1 25 | $-54.7M | — | ||
| Q4 24 | $-162.4M | — | ||
| Q3 24 | $-35.0M | — | ||
| Q2 24 | $-38.1M | — | ||
| Q1 24 | $-42.0M | — |
自由现金流LYELRAPT
| Q4 25 | $-150.8M | — | ||
| Q3 25 | $-28.6M | — | ||
| Q2 25 | $-34.6M | — | ||
| Q1 25 | $-55.0M | — | ||
| Q4 24 | $-162.9M | — | ||
| Q3 24 | $-35.1M | — | ||
| Q2 24 | $-38.4M | — | ||
| Q1 24 | $-42.0M | — |
自由现金流率LYELRAPT
| Q4 25 | -2513400.0% | — | ||
| Q3 25 | -190926.7% | — | ||
| Q2 25 | -432825.0% | — | ||
| Q1 25 | -785485.7% | — | ||
| Q4 24 | -1480527.3% | — | ||
| Q3 24 | -103238.2% | — | ||
| Q2 24 | -295576.9% | — | ||
| Q1 24 | -1401533.3% | — |
资本支出强度LYELRAPT
| Q4 25 | 13000.0% | — | ||
| Q3 25 | 413.3% | — | ||
| Q2 25 | 2100.0% | — | ||
| Q1 25 | 3514.3% | — | ||
| Q4 24 | 4218.2% | — | ||
| Q3 24 | 173.5% | — | ||
| Q2 24 | 2546.2% | — | ||
| Q1 24 | 1000.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
